Comparison of short-term outcomes from the International Oesophago-Gastric Anastomosis Audit (OGAA), the Esophagectomy Complications Consensus Group (ECCG), and the Dutch Upper Gastrointestinal Cancer Audit (DUCA)

Oesophago-Gastric Anastomosis Study Group on behalf of the West Midlands Research Collaborative

Abstract

**Background:** The Esophagectomy Complications Consensus Group (ECCG) and the Dutch Upper Gastrointestinal Cancer Audit (DUCA) have set standards in reporting outcomes after oesophagectomy. Reporting outcomes from selected high-volume centres or centralized national cancer programmes may not, however, be reflective of the true global prevalence of complications. This study aimed to compare complication rates after oesophagectomy from these existing sources with those of an unselected international cohort from the Oesophago-Gastric Anastomosis Audit (OGAA).

**Methods:** The OGAA was a prospective multicentre cohort study coordinated by the West Midlands Research Collaborative, and included patients undergoing oesophagectomy for oesophageal cancer between April and December 2018, with 90 days of follow-up.

**Results:** The OGAA study included 2247 oesophagectomies across 137 hospitals in 41 countries. Comparisons with the ECCG and DUCA found differences in baseline demographics between the three cohorts, including age, ASA grade, and rates of chronic pulmonary disease. The OGAA had the lowest rates of neoadjuvant treatment (OGAA 75.1 per cent, ECCG 78.9 per cent, DUCA 93.5 per cent; \( P < 0.001 \)). DUCA exhibited the highest rates of minimally invasive surgery (OGAA 57.2 per cent, ECCG 47.9 per cent, DUCA 85.8 per cent; \( P < 0.001 \)). Overall complication rates were similar in the three cohorts (OGAA 63.6 per cent, ECCG 59.0 per cent, DUCA 62.2 per cent), with no statistically significant difference in Clavien–Dindo grades (\( P = 0.752 \)). However, a significant difference in 30-day mortality was observed, with DUCA reporting the lowest rate (OGAA 3.2 per cent, ECCG 2.4 per cent, DUCA 1.7 per cent; \( P = 0.013 \)).

**Conclusion:** Despite differences in rates of co-morbidities, oncological treatment strategies, and access to minimal-access surgery, overall complication rates were similar in the three cohorts.

Introduction

Oesophageal cancer is a major cause of global mortality, accounting for more than 436 000 deaths annually. Late presentation frequently means that only 30–40 per cent of patients are suitable for curative treatment options. Oesophagectomy remains an integral part of the curative treatment in this latter group, but is associated with significant morbidity and mortality. Before the establishment of definitions for complications and quality measures by the Esophageal Complications Consensus Group (ECCG) in 2015, it was challenging to evaluate the international variation in postoperative oesophagectomy outcomes. The ECCG has provided postoperative outcomes from 24 selected high-volume centres, setting a benchmark for high-quality oesophageal surgery reporting. The Dutch Upper Gastrointestinal Cancer Audit (DUCA) has also provided detailed outcome data from a nationally centralized oesophageal cancer programme, further highlighting national and international variation in complications.

Patient co-morbidity has a significant impact on postoperative outcomes and plays a critical role in achieving good outcomes, whether surgery involves a minimally invasive or open operation. The Oesophago-Gastric Anastomosis Audit (OGAA) was undertaken in 2018 to provide a comprehensive assessment of preoperative, intraoperative, and postoperative oesophagectomy outcomes, with a detailed appraisal of complications, in
accompanying the ECCG framework. The study aimed to collect data from a large number of centres and countries, encompassing centres with varying levels of experience and patient volumes. Centre inclusion was by open invitation, as opposed to the invitation-only approach used by the international ECCG study and compulsory inclusion in DUCA, in an attempt to include this broader perspective.

The aims of the study were to report comprehensive short-term postoperative outcomes from the OGAA cohort, and to provide detailed comparative analyses against the ECCG and DUCA benchmarking studies.

Methods

The OGAA study was run by the Oesophago-Gastric Anastomosis Study Group, on behalf of the West Midlands Research Collaborative. Centres performing oesophagectomy for cancer were invited to contribute. There was no minimum unit volume to register for the study and participation was voluntary. Committed surgeons from each country were invited to act as national lead as part of the organizing committee. This permitted language-specific dissemination of study material and advertising, to facilitate wider centre recruitment. Opportunities for voluntary participation were circulated through national surgical societies. A dedicated social media team facilitated global engagement of international oesophageal surgical centres through a number of platforms. All endeavours were made to ensure open and inclusive centre recruitment, to provide a comprehensive global cohort. The protocol for this study has been published along with the collaborative model that has successfully delivered a number of international and national cohort studies.

Centres were not required to standardize surgical or management pathways, and no changes were made to individual aspects of patient care as part of the study. Teams of surgeons, surgical trainees, research nurses or medical students prospectively identified eligible patients over a 9-month period from 2 April 2018 to 31 December 2018. Patients were followed for 90 days from the date of surgical resection, with study follow-up closing on 31 March 2019. Data collection teams at each centre were supervised by a consultant surgeon, who took overall responsibility for local study conduct and data validation. No external data validation was performed on submitted data, in keeping with previously published data by the ECCG. Data submitted to DUCA are subject to external validation to ensure completeness and accuracy.

Outcome measures

The primary aim was to assess the comparative frequency of postoperative complications (within 30 days) across the OGAA, ECCG, and DUCA cohorts. Complications were defined by the ECCG framework, and classified based on the Clavien–Dindo grade. Secondary outcomes were reoperation, readmission, and postoperative mortality rates. Outcome data for the ECCG and DUCA cohorts were sourced from the most recent publications at the time of conception of the present study. This therefore encompassed patients undergoing oesophagectomy from January 2015 to December 2016 and from January 2016 to December 2017 respectively. Data on oesophagectomy and gastrectomy were reported separately for the DUCA cohort, and only oesophagectomy data were included in the present analysis. As data were acquired from published materials, individual patient-level data were not available, so statistical adjustment for baseline difference between cohorts was not feasible. This also prevented exclusion of patients from ECCG and DUCA cohorts, such as those with benign disease or without an anastomosis.

Tumour staging was performed in accordance with the eighth edition of the TNM staging classification. Positive tumour margins in the OGAA were defined as tumour identifiable at 1 mm or less, in accordance with the Royal College of Pathologists guidance. However, positive tumour margins in the ECCG and DUCA studies were defined as tumour identifiable at 0 mm, in accordance with College of American Pathologists guidance. Comparison of margin positivity (R status) between the OGAA and ECCG/DUCA was therefore not possible.

Ethical approval and data sharing for OGAA

Ethical approval was dependent on local protocols and was country-specific. It was the responsibility of the local principal investigator of the enrolled unit to ensure that appropriate ethical or audit approval was gained before commencement of the study. Ongoing study approval was maintained locally throughout the duration of the study. In the UK, the study was registered at each site as either a clinical audit or service evaluation, on the basis that the information collected was routine and anonymized with no influence on the clinical care pathway.

Statistical analysis

For variables that were available for all three cohorts, comparisons were done using χ² tests for nominal variables, and Kruskal-Wallis tests for ordinal variables. Where significant differences were detected, post hoc pairwise comparisons were performed using χ² tests or Mann–Whitney U tests, as applicable, with Bonferroni correction for three comparisons applied to the resulting P values. Variables that were reported only for two cohorts were analysed using χ² tests or Mann–Whitney U tests, as applicable. All analyses were carried out using SPSS version 22 (IBM, Armonk, New York, USA), with P < 0.050 deemed indicative of statistical significance throughout.

Results

Between April and December 2018, 2247 oesophagectomies for cancer were included in the OGAA. A summary of the characteristics of this study and those of the ECCG and DUCA cohorts is shown in Table 1. The OGAA included patients from 137 centres across 41 countries (106 centres in high-income countries, 31 centres in low–middle-income countries). Of centres contributing to the OGAA, 71 were located in 13 countries where oesophageal adenocarcinoma (OAC) was the predominant histological type.

The ECCG and DUCA studies included patients from fewer centres (24 and 22 respectively) in fewer countries (14 and 1 respectively). Fourteen centres contributing to the ECCG were located in six countries with a histological predominance of adenocarcinoma (OAC) over squamous cell carcinoma (SCC). The DUCA encompasses centres only in the Netherlands, where the age-standardized incidence per 100 000 population is 4.4 for OAC and 2.0 for SCC.

The OGAA included eight centres that contributed to the ECCG, and four that contributed to the DUCA. Two centres contributed to both the ECCG and DUCA. Of the 137 centres in the OGAA cohort, the approximate case volume was less than 20, 20–60 and over 60 procedures per year in 78, 51, and eight centres, after extrapolating the 9-month numbers collected to provide an annual estimate. Centres in the DUCA and ECCG...
studies performed an average mean of 37 and 56 oesophagectomies per year respectively.

Comparisons of patient characteristics, tumour staging, treatment, and outcomes between the three cohorts are summarized in Table 2–4, with further detail reported in Tables S1–S3.

**Patient characteristics**

Baseline patient characteristics of patients in the three studies are shown in Table 2. The three studies had a similar sex distribution, all having a preponderance of men. A significant difference in age was observed, which increased progressively across the ECCG, OGAA, and DUCA cohorts (22.2, 29.1 and 29.7 per cent of the patients respectively were aged over 70 years; \( P < 0.001 \)). The ECCG cohort tended to have lower BMI (BMI at least 25 kg/m\(^2\): OGAA 55.9 per cent, ECCG 53.1 per cent, DUCA 56.3 per cent; \( P = 0.037 \)), but also had the greatest number of co-morbidities on the basis of ASA grade (ASA grade III or higher: OGAA 30.7 per cent, ECCG 38.5 per cent, DUCA 21.5 per cent; \( P < 0.001 \)).

Specific co-morbidity indices were not reported, although the OGAA and DUCA reported total numbers of co-morbidities, which were significantly higher in the latter (2 or more co-morbidities: OGAA 11.2 per cent, DUCA 29.6 per cent; \( P < 0.001 \)). Assessment of individual co-morbidities showed the DUCA to have the highest rate of chronic pulmonary disease, which was almost twice that of the other cohorts (OGAA 13.7 per cent, ECCG 10.5 per cent, DUCA 20.2 per cent; \( P < 0.001 \)). Of the other co-morbidities reported, the ECCG had the highest rates of both congestive heart failure (OGAA 3.0 per cent, ECCG 4.6 per cent, DUCA 0.7 per cent; \( P < 0.001 \)) and peripheral vascular disease (OGAA 5.2 per cent, ECCG 6.8 per cent, DUCA 4.5 per cent; \( P = 0.03 \)), and the OGAA had the highest rate of moderate-to-severe renal disease (OGAA 2.6 per cent, ECCG 1.3 per cent, DUCA 1.3 per cent; \( P = 0.001 \)).

Rates of diabetes mellitus were similar in the three cohorts (OGAA 12.0 per cent, ECCG 13.5 per cent, DUCA 14.5 per cent; \( P = 0.089 \)). Comparison of pathological tumour staging between the three cohorts showed the OGAA to have more advanced tumours, with the highest T and N categories, followed by the ECCG and DUCA (pT3 or higher: OGAA 49.8 per cent, ECCG 44.6 per cent, DUCA 38.8 per cent; \( P < 0.001 \); pN+: OGAA 46.2 per cent, ECCG 42.6 per cent, DUCA 39.3 per cent; \( P < 0.001 \)) (Table 3).

**Treatment variation**

Data on treatment and tumour staging across the three cohort studies are presented in Table 3. The DUCA contained higher rates of neoadjuvant chemoradiotherapy (CRT) and minimally invasive surgery (CRT rate: OGAA 35.6 per cent, ECCG 46.1 per cent, DUCA 87.8 per cent; \( P < 0.001 \); minimally invasive approach: OGAA 57.2 per cent, ECCG 47.9 per cent, DUCA 85.8 per cent; \( P < 0.001 \)), with a greater proportion of three-stage operations (abdomen, chest, neck), resulting in higher rates of cervical anastomoses (OGAA 22.8 per cent, ECCG 37.9 per cent, DUCA 43.0 per cent; \( P < 0.001 \)). Comparisons between the OGAA and ECCG showed smaller differences, although the former had higher rates of minimally invasive surgery, whereas the ECCG had higher rates of neoadjuvant CRT and neck anastomoses.

**Postoperative outcomes**

Overall complication rates were similar in the three studies (OGAA 63.6 per cent, ECCG 59.0 per cent, DUCA 62.2 per cent; \( P = 0.752 \)), with no significant difference in complication severity, as classified by the highest Clavien–Dindo grade (Fig. 1). Despite this, rates of individual complication types differed between the studies (Table 4). For example, the OGAA had the highest rates of respiratory and infective complications, but significantly lower rates of gastrointestinal and cardiac complications. Rates of anastomotic leak and conduit necrosis in the OGAA were 14.2 and 2.7 per cent respectively. Combining these outcomes, it was found that the composite anastomotic leak/conduit necrosis rate differed significantly between the cohorts, being highest in the DUCA, and lowest in the ECCG cohort (OGAA 14.6 per cent, ECCG 11.4 per cent, DUCA 19.0 per cent; \( P < 0.001 \)). There were no significant differences in chyle leak rates between pairs of studies.

Mortality rates at 30 and 90 days were similar in the OGAA and ECCG cohorts (90-day mortality: OGAA 4.5 per cent, ECCG 4.5 per cent, \( P = 0.967 \)). The DUCA did not report 90-day deaths, but had a significantly lower 30-day mortality rate than the other studies (30-day mortality: OGAA 3.2 per cent, ECCG 2.4 per cent, DUCA 1.7 per cent; \( P = 0.013 \)). The Dutch audit had a significantly higher 30-day readmission rate than the other two cohorts (OGAA 11.5 per cent, ECCG 10.2 per cent, DUCA 14.4 per cent; \( P < 0.001 \)).

**Discussion**

Postoperative oesophagectomy outcomes across an unselected global cohort have been evaluated and compared with those in previous benchmarking studies from the ECCG and DUCA. Overall rates of complications were comparable in all three studies. The OGAA and ECCG reported similar 30-day mortality rates, but the DUCA had significantly lower mortality rates than the OGAA. This lower mortality rate may reflect a well resourced, centralized, national oesophageal cancer programme facilitating an ability to recognize and rescue the deteriorating patient. Evidence from the Agency for Healthcare Research and Quality

---

**Table 1 Summary of study characteristics of cohort studies from the OGAA, ECCG and DUCA**

| No. of centres | OGAA | ECCG | DUCA |
|----------------|------|------|------|
| 137            | 24   | 22   |
| No. of countries | 41   | 14   | 1    |
| No. of patients | 2247 | 2704 | 1617 |
| Inclusion dates | Apr 2018 to Dec 2018 | Jan 2015 to Dec 2016 | Jan 2016 to Dec 2017 |
| Centre volume | Open invitation (national leads dissemination, national societies, social media) | High volume only | Invite only (2020—open to new applications) |
| Centre inclusion | Any | Any | Any |
| Type of surgery | Oesophago-Gastric only | Oesophago-Gastric only | Oesophago-Gastric and gastrectomy |
| Indication | Malignancy only | Malignancy only | Malignancy only |
| Definition of an involved margin | \(<1\) mm² | 0 mm² | 0 mm² |
| Centres enrolled in OGAA | – | – | – |

OGAA, Oesophago-Gastric Anastomosis Audit; ECCG, Esophagectomy Complications Consensus Group; DUCA, Dutch Upper Gastrointestinal Cancer Audit.
Nationwide Readmission Database\textsuperscript{23} showed that failure-to-rescue rates were 21.2 per cent in low-volume centres, compared with 13.4 per cent in high-volume centres.

Patient selection has often been perceived as a key determinant of successful postoperative outcomes. Although definitive CRT has good outcomes for SCC, its efficacy is limited for adenocarcinoma\textsuperscript{24–26}. The extent to which patient selection contributed to differences in patient outcome between the three studies remains elusive. The Dutch audit reported the lowest 30-day mortality rate, but contained the highest rate of chronic pulmonary disease and had the greatest proportion of patients aged over 70 years. The OGAA cohort, on the other hand, contained more patients with locally advanced disease (higher T categories and rates of nodal positivity). This might reflect access to, and use of, diagnostic and staging modalities, as well as availability and cultural attitudes to non-surgical treatments (indicated by lower neoadjuvant treatment rates), especially in middle- and low-income societies\textsuperscript{13}. The OGAA also had the highest rates of conduit necrosis, which may highlight the challenges of maintaining high surgical standards in lower-volume units. Despite these differences between the three studies, overall complication rates were broadly similar.

There is conflicting evidence regarding the impact of minimally invasive oesophagectomy compared with open surgery on complication rates and other outcomes\textsuperscript{27–30}. The TIME and MIRO trials, which demonstrated the superiority of minimally invasive techniques, have further driven rapid adoption\textsuperscript{27,30,31}, although it should be recognized that transition to a new operative technique can be associated with increased complications that are likely to influence outcomes outside a trial setting\textsuperscript{32,33}. The DUCA involved significantly more minimally invasive surgery than the OGAA and ECCG studies, yet had similar levels of complications. The explanation may be complex. Rates of respiratory complications did not differ significantly between the OGAA and DUCA, despite the significantly higher rates of chronic pulmonary disease in the DUCA cohort, but there were higher rates of open

| Table 2 Baseline demographics of OGAA, ECCG, and DUCA cohort studies |
|-----------------------------------------------|
| % of patients       | Overall \( P \) | P for pairwise comparisons\( ^{\text{§}} \) |
| OGAA  | ECCG  | DUCA  | OGAA versus ECCG | OGAA versus DUCA | ECCG versus DUCA |
| Male sex          |       |       |          |             |                   |
| Age (years)       |       |       |          |             |                   |
| < 40             | 78.6  | 77.5  | 76.0     | 0.151        | –              | –              |
| 41–50            | 2.5   | 2.4   | 0.4      | < 0.001\(^{\dagger}\) | 0.001\(^{\ddagger}\) | –              |
| 51–60            | 8.1   | 8.0   | 4.7      | –             | –              | –              |
| 61–70            | 24.5  | 26.7  | 19.5     | –             | –              | –              |
| > 80             | 35.8  | 40.7  | 45.7     | –             | –              | –              |
| BMI (kg/m\(^2\))|       |       |          |             |                   |
| < 18.5           | 4.2   | 6.8   | 2.9      | 0.037\(^{\dagger}\)  | 0.039\(^{\ddagger}\) | 1.000\(^{\ddagger}\)  | 0.372\(^{\ddagger}\) |
| 18.5–25.0        | 39.9  | 40.1  | 40.8     | –             | –              | –              |
| 25.0–30.0        | 35.3  | 33.6  | 39.9     | –             | –              | –              |
| > 30             | 20.6  | 19.5  | 16.4     | –             | –              | –              |
| Smoking status   |       |       |          |             |                   |
| Never smoked     | 38.6  | –     | –        | –             | –              | –              |
| Ex-smoker (≥ 6 weeks) | 40.3 | –     | –        | –             | –              | –              |
| Ex-smoker (< 6 weeks) | 5.5  | –     | –        | –             | –              | –              |
| Current smoker   | 15.6  | –     | –        | –             | –              | –              |
| ASA fitness grade|       |       |          |             |                   |
| I                | 13.3  | 15.2  | 15.8     | < 0.001\(^{\dagger}\) | < 0.001\(^{\ddagger}\) | < 0.001\(^{\ddagger}\) | < 0.001\(^{\ddagger}\) |
| II               | 56.1  | 46.2  | 62.7     | –             | –              | –              |
| III              | 29.7  | 36.7  | 21.1     | –             | –              | –              |
| IV               | 1.0   | 1.8   | 0.4      | –             | –              | –              |
| V                | 0.0   | 0.0   | 0.0      | –             | –              | –              |
| No. of co-morbidities |       |       |          |             |                   |
| 0                | 59.3  | –     | 46.6     | < 0.001\(^{\dagger}\) | –              | –              |
| 1                | 29.5  | –     | 23.8     | –             | –              | –              |
| > 2              | 11.2  | –     | 29.6     | –             | –              | –              |
| ECOG status      |       |       |          |             |                   |
| 0                | 60.9  | –     | –        | –             | –              | –              |
| 1                | 32.8  | –     | –        | –             | –              | –              |
| > 2              | 6.3   | –     | –        | –             | –              | –              |
| Diabetes mellitus|       |       |          |             |                   |
| No               | 87.9  | 86.5  | 85.5     | 0.089\(^{\dagger}\)  | –              | –              |
| Uncomplicated    | 11.2  | 12.9  | 13.7     | –             | –              | –              |
| End-organ damage | 0.8   | 0.6   | 0.8      | –             | –              | –              |
| Myocardial infarction | 6.4 | 5.4   | 5.3      | 0.226         | –              | –              |
| Chronic pulmonary disease | 13.7 | 10.5  | 20.2     | < 0.001       | 0.011          | < 0.001        | < 0.001        |
| Peripheral vascular disease | 5.2 | 6.8   | 4.5      | 0.003         | 0.051          | 1.000          | 0.005          |
| Moderate–severe renal disease | 2.6  | 1.3   | 1.3      | 0.001         | 0.003          | 0.016          | 1.000          |

Data are reported only as percentages, in order to simplify the table; the associated numerators and denominators are reported in Table S1. OGAA, Oesophago-Gastric Anastomosis Audit; ECCG, Esophagectomy Complications Consensus Group; DUCA, Dutch Upper Gastrointestinal Cancer Audit; ECOG, Eastern Cooperative Oncology Group. \( \chi^2 \) test, except\(^{\dagger}\) Kruskal–Wallis test and\(^{\ddagger}\) Mann–Whitney \( U \) test for ordinal variables. \(^{\ddagger}\)Bonferroni-corrected \( \chi^2 \) test, except\(^{\ddagger}\) Bonferroni-corrected Mann–Whitney \( U \) test for ordinal variables. \(^{\ddagger}\)Pairwise comparisons not applicable as data available for only two cohorts.
surgery in the OGAA cohort suggesting that the minimally invasive approach may have offset the risk of pulmonary complications in the DUCA cohort.

CRT was also used more frequently in the DUCA cohort, where 87.8 per cent of patients received this treatment. Global variations in neoadjuvant treatment options are largely explained by centres that favour neoadjuvant chemotherapy based on evidence from the MAGIC, OE02, and OE05 trials. High uptake of CRT in the Netherlands is likely to have been influenced by the success of the CROSS trial. The absence of increased rates of overall complications in the DUCA cohort compared with the other studies supports existing evidence that neoadjuvant CRT does not increase overall complications.

Anastomotic leakage is generally regarded as a serious complication of oesophagectomy because of the risk of associated sepsis. Leak rates were highest in the DUCA group probably reflecting the high rates of anastomoses performed in the neck, and the highest rates of minimally invasive surgery, both of which are recognized to contribute to higher leak rates. The extent to which neoadjuvant CRT contributes to anastomatic leak is controversial, including whether the anastomosis lies within the radiation field or whether the stomach has been irradiated. The combination of chronic pulmonary disease and CRT has been shown to potentially double rates of anastomotic leakage, so these features could also have contributed to the higher leak rates in the DUCA cohort. Despite having the highest rate of anastomotic leak, the DUCA cohort had the lowest 30-day mortality rate, suggesting that anastomotic leaks per se are not critical determinants of mortality, or that a cervical leak is less likely to result in death than an intrathoracic leak. The higher readmission rate in the DUCA cohort may indicate a lower threshold for readmission that may itself have influenced outcomes.

A specific focus of the OGAA study was capturing clinically relevant data at a patient-, disease- and operation-specific level.
Table 4 Intraoperative and postoperative outcomes across the OGAA, ECCG, and DUCA cohort studies

| % of patients | Overall P \(\dagger\) | P for pairwise comparisons \(\ddagger\) |
|---------------|---------------------|---------------------|
|               | OGAA | ECCG | DUCA | OGAA versus ECCG | OGAA versus DUCA | ECCG versus DUCA |
| **Intraoperative complications** | | | | | | |
| Highest Clavien–Dindo grade | | | | | | |
| No complication | 2.5 | – | 5.5 | < 0.001 | – | – |
| I | 36.4 | 41.0 | 37.8 | 0.752 | – | – |
| II | 12.0 | 7.5 | 9.4 | – | – | – |
| IIIA | 26.2 | 20.4 | 23.7 | – | – | – |
| IIIB | 9.7 | 14.2 | 12.0 | – | – | – |
| IV | 7.1 | 6.6 | 8.0 | – | – | – |
| V | 4.3 | 6.4 | 6.9 | – | – | – |
| Gastrointestinal complications | | | | | | |
| No leak | 11.5 | 22.4 | 24.2 | < 0.001 | < 0.001 | < 0.001 | 0.501 |
| Type 1 | 2.9 | 5.2 | 2.8 | < 0.001 | < 0.001 | 1.000 | < 0.001 |
| Type 2 | 7.0 | 3.3 | 5.7 | < 0.001 | 0.008 | < 0.001 | < 0.001 |
| Type 3 | 3.4 | 4.8 | 8.1 | < 0.001 | 0.008 | < 0.001 | < 0.001 |
| Conduit necrosis | | | | | | |
| No necrosis | 97.3 | 98.8 | 99.2 | < 0.001 | < 0.001 | < 0.001 | 0.702 |
| Type 1 | 1.2 | 0.1 | 0.1 | – | – | – |
| Type 2 | 0.7 | 0.3 | 0.2 | – | – | – |
| Type 3 | 0.8 | 0.9 | 0.6 | – | – | – |
| Combined anastomotic leak/conduit necrosis | 14.6 | 11.4 | 19.0 | < 0.001 | 0.002 | < 0.001 | < 0.001 |
| Chyle leak | 5.4 | 4.0 | 4.1 | 0.043 | 0.061 | 0.203 | 1.000 |
| Vocal cord injury | 4.6 | 4.7 | 7.2 | < 0.001 | 1.000 | 0.002 | 0.002 |
| Respiratory complications | 35.9 | 27.8 | 32.7 | < 0.001 | < 0.001 | 0.117 | 0.002 |
| Cardiac complications | 13.1 | 16.8 | 17.1 | < 0.001 | < 0.001 | 0.002 | 1.000 |
| Diaphragmatic complications | 1.8 | 2.9 | 1.9 | 0.020 | 0.046 | 1.000 | 0.108 |
| Infective complications | 19.4 | 14.2 | 7.4 | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Urological complications | 5.9 | 8.5 | 4.1 | < 0.001 | 0.003 | 0.038 | < 0.001 |
| Return to theatre | 12.0 | 15.7 | 12.9 | < 0.001 | < 0.001 | 1.000 | 0.033 |
| 30-day readmission | 11.5 | 10.2 | 14.4 | < 0.001 | 0.423 | 0.022 | < 0.001 |
| 30-day mortality | 3.2 | 2.4 | 1.7 | 0.013 | 0.315 | 0.011 | 0.318 |
| 90-day mortality | 4.5 | 4.5 | – | 0.967 | – | – | – |

Data are reported only as percentages, in order to simplify the table; the associated numerators and denominators are reported in Table S3. The Oesophago-Gastric Anastomosis Audit (OGAA) data exclude 79 patients who either died in hospital, or for whom follow-up was not available. ECCG, Esophagectomy Complications Consensus Group; DUCA, Dutch Upper Gastrointestinal Cancer Audit; \(\dagger\) \(\chi^2\) test, except \(\ddagger\) Kruskal–Wallis test for ordinal variables. \(\ddagger\) Bonferroni-corrected \(\chi^2\) test, except \(\ddagger\) Bonferroni-corrected Mann–Whitney \(U\) test for ordinal variables. \(\ddagger\) Pairwise comparisons not applicable as data available for only two cohorts.

Fig. 1 Complication rate by highest Clavien–Dindo grade in OGAA, ACCG, and DUCA studies

OGAA, Oesophago-Gastric Anastomosis Audit; ECCG, Esophagectomy Complications Consensus Group; DUCA, Dutch Upper Gastrointestinal Cancer Audit. \(P = 0.752\) (Kruskal–Wallis test).

Fig. 1 Complication rate by highest Clavien–Dindo grade in OGAA, ACCG, and DUCA studies. OGAA, Oesophago-Gastric Anastomosis Audit; ECCG, Esophagectomy Complications Consensus Group; DUCA, Dutch Upper Gastrointestinal Cancer Audit. \(P = 0.752\) (Kruskal–Wallis test).

In order to minimize reporting bias in the study, the short duration of data collection was designed to minimize effects due to changes in practice. Despite the overall success in achieving these goals, there are limitations. ECCG and DUCA data were extracted from relevant publications. Data were not available at a patient level; therefore, statistical adjustment for preoperative and intraoperative factors was not possible when evaluating outcomes. The inclusion of patients without cancer in the ECCG and DUCA cohorts should be noted, and it was not possible to comment on the success of reported evaluation of neoadjuvant treatments and how this may have influenced short-term outcomes. Different pathological classifications were used to determine margin positivity, precluding comparisons between all three studies. For the OGAA, data were verified by each unit’s lead investigator, although no specific data verification process was undertaken. Previous data verification in national and international observational studies has shown high accuracy.

A standardized internationally agreed data set covering not only demographics, resources, and surgical volumes, the similarity in overall complication rates in all three studies suggests that oesophagectomy can be performed safely at an international level.
The present study has also highlighted fundamental shortcomings when comparing international outcome data for oesophagectomy. The development of a standardized data set for future studies should be considered.

Acknowledgements

The authors are grateful to the Birmingham Surgical Trials Consortium at the University of Birmingham for use of its servers for secure online data collection.

Disclosure. The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS Open online.

References

1. Kamangar F, Nasrollahzadeh D, Safiri S, Sepanlou SG, Fitzmaurice C, Ikuta KS et al. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:582–597.

2. Maynard N. National Oesopha-Gastro-Cancer Audit 2019. London: Royal College of Surgeons of England, 2019.

3. Maynard M, Chadwick G, Varagunam M, Brand C, Cromwell D, Riley S et al. National Oesophago-Gastric Cancer Audit 2018. London: Royal College of Surgeons of England, 2018.

4. Low DE, Kuppusamy MK, Alderson D, Cecconello I, Chang AC, Darling G et al. Benchmarking complications associated with esophagectomy. Ann Surg 2019;269:291–298.

5. van der Werf LR, Busweiler LAD, van Sandick JW, van Berge Henegouwen MI, Wijnhoven BPL. Reporting national outcomes after esophagectomy and gastrectomy according to the Esophageal Complications Consensus Group (ECCG). Ann Surg 2020;271:1095–1101.

6. Low DE, Alderson D, Cecconello I, Chang AC, Darling GE, D’Journo XB et al. International consensus on standardization of data collection for complications associated with esophagectomy: Esophageal Complications Consensus Group (ECCG). Ann Surg 2015;262:286–294.

7. Moskovitz AH, Rizk NP, Venkatraman E, Bains MS, Flores RM, Park BJH et al. Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2006;82:2031–2036.

8. Paulus E, Ripat C, Koshenko V, Prescott AT, Sethi K, Stuart H et al. Esophagectomy for cancer in octogenarians: should we do it? Langenbeck’s Arch Surg 2017;402:539–545.

9. Schmidt HM, Gisbertz SS, Moons J, Rouvelas I, Kauppi J, Brown A et al. Defining benchmarks for transthoracic esophagectomy. Ann Surg 2017;266:814–821.

10. Yoshida N, Yamamoto H, Baba H, Miyata H, Watanabe M, Toh Y et al. Can minimally invasive esophagectomy replace open esophagectomy for esophageal cancer? Latest analysis of 24 233 esophagectomies from the Japanese National Clinical Database. Ann Surg 2019;272:118–124.

11. Mariette C, Markar SR, Dabaku-Uonyi T, Han S, Meunier B, Pezet D, Collet D et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med 2019;380:152–162.

12. Evans RPT, Singh P, Nepogodiev D, Bundred J, Kamarajah S, Jefferies B, et al. Study protocol for a multicenter prospective cohort study on esophagogastrectomy anastomoses and anastomotic leak (the Oesophago-Gastric Anastomosis Audit/OGAA). Dis Esophagus 2019;33:doz007.

13. Bundred JR, Kamarajah SK, Siaw-Acheampong K, Nepogodiev D, Jefferies B, Singh P et al. International variation in surgical practices in units performing oesophagectomy for oesophageal cancer: a unit survey from the Oesophago-Gastric Anastomosis Audit (OGAA). World J Surg 2019;43:2874–2884.

14. Bhanu A, Ademuyiwa AO, Aguiler ML, Alexander P, Al-Saqq SW, Borda-Luque G et al. Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study. Lancet Infect Dis 2018;18:516–525.

15. Vohra RS, Griffiths EA, Alderson D, Pasquali S, Buja A, Sutton AJ et al. Cost-effectiveness of emergency versus delayed laparoscopic cholecystectomy for acute gallbladder pathology. Br J Surg 2016;104:98–107.

16. Vohra RS, Spreadborough P, Johnstone M, Marriott P, Bhanu A, Alderson D et al.; West Midlands Research Collaborative. Protocol for a multicentre, prospective, population-based cohort study of variation in practice of cholecystectomy and surgical outcomes (the CholecS study). BMJ Open 2015;5:e006399.

17. Harrison E. Quality and outcomes in global cancer surgery: protocol for a multicentre, international, prospective cohort study (GlobalSurg 3). BMJ Open 2019;9:e026646.

18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–215.

19. Rice TW, Patil DT, Blackstone EH. AJCC/IJCC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg 2017;6:119–130.

20. Grabbs H, Mapstone NP, MN, Royal College of Pathologists. Standards and Datasets for Reporting Cancers. Dataset for Histopathological Reporting of Oesophageal and Gastric Carcinoma, October 2019. v3.1-58.

21. College of American Pathologists. Protocol for the Examination of Specimens from Patients with Carcinoma of the Esophagus. https://documents.cap.org/protocols/cp-esophagus-2016-v3200.pdf (3 January 2020, date last accessed).

22. Arnold M, Ferlay J, Van Berge Henegouwen MI, Soerjomataram I. Global burden of oesophageal and gastric cancer by histology and subtype in 2018. Gut 2020;69:1564–1571.

23. Abdelsattar ZM, Habermann E, Borah BJ, Moriarty JP, Rojas RL, Blackmon SH. Understanding failure to rescue after esophagectomy in the United States. Ann Thorac Surg 2020;109:865–871.

24. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160–1168.

25. Stahli M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeben A et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310–2317.

26. Kamarajah SK, Phillips AW, Hanna GB, Markar SR. Definitive chemoradiotherapy compared to neoadjuvant chemoradiotherapy with esophagectomy for locoregional esophageal cancer. Ann Surg 2020;380:doz130–130.

27. Markar SR, Ni M, Gisbertz SS, van der Werf L, Straatman J, van der Peet D et al. Implementation of minimally invasive esophagectomy from a randomized controlled trial setting to national practice. J Clin Oncol 2020;38:2130–2139.
28. Seesing MFJ, Gisbertz SS, Goense L, Van Hillegersberg R, Kroon HM, Lagarde SM et al. A propensity score matched analysis of open versus minimally invasive transthoracic esophagectomy in the Netherlands. Ann Surg 2017;266:839–846.

29. Siaw-Acheampong K, Kamarajah SK, Gujuri R, Bundred JR, Singh P, Griffiths EA. Minimally invasive techniques for transthoracic oesophagectomy for oesophageal cancer: systematic review and network meta-analysis. BJS Open 2020;4:787–803.

30. van der Sluis PC, van der Horst S, May AM, Schippers C, Brosens LAA, Joore HCA. Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: a randomized controlled trial. Ann Surg 2019;269:621–630.

31. Mariette C, Meunier B, Pezet D, Dalban C, Collet D, Thomas PA et al. Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicenter, open-label, randomized phase III controlled trial, the MIRO trial. J Clin Oncol 2015;33(Suppl):5.

32. van Workum F, Stenstra MHBC, Berkelmans GHK, Slaman AE, van Berge Henegouwen MI, Gisbertz SS et al. Learning curve and associated morbidity of minimally invasive esophagectomy: a retrospective multicenter study. Ann Surg 2019;269:88–94.

33. Kingma BF, Grimminger PP, van der Sluis PC, van Det MJ, Kouwenhoven EA, Chao YK et al.: UGIRA Study Group. Worldwide techniques and outcomes in robot-assisted minimally invasive esophagectomy (RAMIE): results from the Multicenter International Registry. Ann Surg 2020;epub ahead of print 9.11.2020.

34. Girling DJ, Bancewicz J, Clark PI, Smith DB, Donnelly RJ, Fayers PM et al. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727–1733.

35. Cunningham D, Allum WH, Stening SP, Thompson JN, Van de Velde CJH, Nicolson M et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.

36. Alderson D, Cunningham D, Nankivell M, Blazey JM, Griffin S M, Crellin A et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC EOF3): an open-label, randomised phase 3 trial. Lancet Oncol 2017;18:1249–1260.

37. Van Hagen F, Huishof MCCM, Van Lanschot JJB, Steyerberg EW, Van Berge Henegouwen MI, Wijnhoven BFL et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084.

38. Nederlof N, Slaman AE, van Hagen P, van der Gaast A, Siankamenac K, Gisbertz SS et al.; CROSS Study Group. Using the comprehensive complication index to assess the impact of neoadjuvant chemoradiotherapy on complication severity after esophagectomy for cancer. Ann Surg Oncol 2016;23:3964–3971.

39. Gooszen JAH, Goense L, Gisbertz SS, Ruurda JP, van Hillegersberg R, van Berge Henegouwen MI. Intrathoracic versus cervical anastomosis and predictors of anastomotic leakage after oesophagectomy for cancer. Br J Surg 2018;105:552.

40. Ryan CE, Paniccia A, Meguid RA, McCarter MD. Transthoracic anastomotic leak after esophagectomy: current trends. Ann Surg Oncol 2017;24:281–290.

41. Kassis ES, Kosinski AS, Ross P, Koppes KE, Donahue JM, Daniel VC. Predictors of anastomotic leak after esophagectomy: an analysis of the society of thoracic surgeons general thoracic database. Ann Thorac Surg 2013;96:1919–1926.

42. Hall BR, Flores LE, Parshall ZS, Shostrom VK, Are C, Reames BN. Risk factors for anastomotic leak after esophagectomy for cancer: a NSQIP procedure-targeted analysis. J Surg Oncol 2019;120:661–669.

43. Kamarajah SK, Lin A, Tharmaraja T, Bharwada Y, Bundred JR, Nepogodiev D et al. Risk factors and outcomes associated with anastomotic leaks (AL) following oesophagectomy: a systematic review and meta-analysis. Dis Esophagus;2020;33:doz089.

44. Klevébro F, Friesland S, Hedman M, Tsai JA, Lindblad M, Rouvelas I et al. Neoadjuvant chemoradiotherapy may increase the risk of severe anastomotic complications after esophagectomy with cervical anastomosis. Langenbecks Arch Surg 2016;401:323–331.

45. Goense L, van Rossum PSN, Ruurda JP, van Vulpun M, Mook S, Meijer GJ et al. Radiation to the gastric fundus increases the risk of anastomotic leakage after esophagectomy. Ann Thorac Surg 2016;102:1798–1804.

46. Klevébro F, Elliott JA, Slaman A, Vermeulen BD, Kamiya S, Rosman C et al. Cardiorespiratory comorbidity and postoperative complications following esophagectomy: a European multicenter cohort study. Ann Surg Oncol 2019;26:2864–2873.

47. Bhangu A, Chapman SJ, Glasbey J, Kelly M, Khatzi C, Nepogodiev D et al. Impact of postoperative non-steroidal anti-inflammatory drugs on adverse events after gastrointestinal surgery. Br J Surg 2014;101:1413–23.

48. Glasbey JC, Nepogodiev D, Battersby N, Bhangu A, El-Hussuna A, Frasson M et al. The impact of stapling technique and surgeon specialization on anastomotic failure after right-sided colorectal resection: an international multicentre, prospective audit. Colorectal Dis 2018;20:1028–1040.

49. van der Werf LR, Voeten SC, van Löe CMM, Karthaus EG, Wouters MWJM, Prins HA. Data verification of nationwide clinical quality registries. BJS Open 2019;3:857–864.

50. TM Mackay, EM Gleeson, UF Wellner, C Williamsson, OR Busch, BG Koerkamp et al.; Global Audits on Pancreatic Surgery Group (GAPASURG). Transatlantic registries of pancreatic surgery in the United States of America, Germany, the Netherlands, and Sweden: comparing design, variables, patients, treatment strategies, and outcomes. Surgery.